Observational Study of Zymfentra Infliximab-dyyb for Adults with Crohns Disease, Ulcerative Colitis, or Indeterminate Colitis Over One Year
Led by University of North Carolina, Chapel Hill · Updated on 2026-08-05
200
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how effective Zymfentra infliximab-dyyb is in treating adults with Crohns disease, ulcerative colitis, or inflammatory bowel disease unclassified. This observational study focuses on patients prescribed Zymfentra as part of their regular care to see if it reduces symptoms over one year. The study is sponsored by the University of North Carolina, Chapel Hill.
Participants receive Zymfentra treatment through their standard medical care. They will be followed for one year while answering online surveys about their bowel habits and other health outcomes at specific weeks throughout the study period. The study collects patient-reported outcomes and clinical remission data at multiple time points including weeks 0, 1, 2, 4, 6, 10, 14, 18, 24, 36, and 52.
During participation, patients complete questionnaires that assess symptoms, depression, anxiety, social satisfaction, fatigue, and work productivity. Clinical remission is evaluated using established disease activity indices. Researchers also monitor mucosal healing through standard tests and endoscopic scores when available. The total study duration for each participant is one year, with ongoing monitoring of responses and disease activity.
CONDITIONS
Brief Title
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Research Team
S
Susan Jackson
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adults aged 18 years or older with Crohn's disease, ulcerative colitis, or inflammatory bowel disease unclassified
Starting Zymfentra (IFX-dyyb) at week 10 as part of standard intravenous infliximab induction therapy or switching from intravenous infliximab originator or biosimilars during maintenance therapy to Zymfentra
Anticipated follow-up by the participating center for the next 12 months
Diagnosis confirmed by clinical, radiographic, endoscopic, and histologic criteria including symptoms and objective evidence of inflammation
You will not qualify if you...
Unable to provide informed consent
Non-English speaking
Patients presenting for a one-time consultation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Observation and Data Collection
Duration - 1 year
Participants prescribed Zymfentra as part of their regular care will answer online surveys about their bowel habits and symptoms. Researchers will collect patient-reported outcomes and monitor disease activity over one year.
Online surveys at multiple weeks: 0, 1, 2, 4, 6, 10, 14, 18, 24, 36, and 52
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Phase 1 Study Evaluating Safety and Effects of PVT401 Nanomedicine with Single and Multiple Intravenous Doses in Healthy Adults
Phase 2 Study Evaluating Safety and Effectiveness of Multiple Treatments for Moderate to Severe Crohns Disease and Ulcerative Colitis in Adults
Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of BDHK-2009 Tablets in Healthy Adults Aged 18 to 55
Safety and Effectiveness Study of INT-210 Capsules in Adults With Active Ulcerative Colitis
Phase 2 Study to Test the Safety and Effectiveness of HSK47388 for Moderate to Severe Ulcerative Colitis
Phase 2b Randomized Study Evaluating AC-101 Tablets for Moderately to Severely Active Ulcerative Colitis
Evaluating Safety and Effects of Oral MB-001 Capsules Compared to Placebo in Adults with Moderately to Severely Active Ulcerative Colitis
Vedolizumab Treatment for Children and Teens With Moderate to Severe Crohns Disease
Phase 3 Study to Evaluate Safety and Effectiveness of IV Vedolizumab as Maintenance Therapy
For Pediatric Patients Responding to Initial Vedolizumab Infusions
Observational Study of Vedolizumab Subcutaneous Injection in Adults with Moderate to Severe Ulcerative Colitis or Crohns Disease in South Korea
Evaluating Fecal Microbiota Transplant and Anti-Inflammatory Diet with 5-ASA for Treating Mild to Moderate Active Ulcerative Colitis in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL).
Development and initial psychometric validation of a patient-reported outcome measure for Crohn's perianal fistula: the Crohn's Anal Fistula Quality of Life (CAF-QoL) scale.
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
Marla C Dubinsky, David B Clemow, Theresa Hunter Gibble...